Nanollose logo
NC6

Nanollose

Pharmaceuticals, Biotechnology & Life Sciences

Nanollose is an Australian biotechnology company focused on developing sustainable materials, particularly Nullarbor fibre, a tree-free rayon alternative made from microbial cellulose. Their technology aims to transform liquid waste into rayon fibre for clothing, minimizing environmental impact and offering a scalable solution for the textile industry. The company is positioned to capitalize on the growing demand for eco-friendly and sustainable textile options.

Short position

short percentage0.00%
reported shorts1.2K
shares on issue409.827M

Nanollose (ASX:NC6) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,214 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. NC6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Nanollose (NC6) financials

Results, ratios and statements

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue
$3.5K (source: ASX (Markit))vs $11.9K (source: ASX (Markit)) (FY25)
ASX (Markit), as at 29 Sep 2026
NPAT
−$2.4M (source: ASX (Markit))vs −$1.4M (FY25)
ASX (Markit), as at 29 Sep 2026
EPS (diluted)
−$0.007 (source: Derived: trailing 12 months at year end)vs −$0.007 (FY25)
Derived: trailing 12 months at year end, as at 29 Sep 2026
Rev YoY
−70.4%FY
EPS YoY
n/aTTM
  • ASX (Markit)
  • Derived: trailing 12 months at year end

Summary of Appendix 4E & Annual Report to shareholders, 31 Aug 2026

Nanollose reported a 68% increase in its full-year loss to $2.39 million (from $1.43 million) with no revenue, and paid no dividends. The company is focusing on its Nullarbor™ fibre commercial pathway and plans to build a single Pilot Facility in Western Australia as its principal FY2027 objective.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin
n/a
Operating margin
n/a
Net margin
−67,628.0%
FCF margin
n/a
ROE
n/a
ROA
n/a
FCF conversion
n/a
Net debt (excl. leases)
n/a
Net debt / EBITDA
n/a
Current ratio
n/a
Interest cover
n/a
Cash dividends paid / net profit
n/a
Market cap
n/a (no share count we can vouch for)
P/E
n/a
P/B
n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

NC6 income, newest period first, figures in AUD
Line itemFY26FY25FY24FY23
Revenue$3.5K (source: ASX (Markit))$11.9K (source: ASX (Markit))$12.5K$38.1K
Gross profitn/an/a$12.5K$38.1K
Operating incomen/a−$1.6M−$1.4M−$1.5M
EBITDAn/a−$1.4M−$1.1M−$1.3M
EBITn/a−$1.4M−$1.1M−$1.3M
Interest expensen/a$35.0K$21.9K$1.2K
Pretax incomen/a−$1.4M−$1.2M−$1.3M
Taxn/a$0$0$0
NPAT−$2.4M (source: ASX (Markit))−$1.4M−$1.2M−$1.3M
Net interest incomen/a−$32.6K−$17.4K$15.9K
EPS basic−$0.007 (source: Derived: trailing 12 months at year end)−$0.007−$0.007−$0.009
EPS diluted−$0.007 (source: Derived: trailing 12 months at year end)−$0.007−$0.007−$0.009
Sharesn/a305.1M176.9M153.1M
  • ASX (Markit)
  • Derived: trailing 12 months at year end